The study found that recurrence of the thyroid cancer was found in 1.8%, 14.3%, and 24% of patients in groups A, B, and C, respectively. Specifically, among patients with undetectable thyroglobulin, negative ultrasound, and positive thyroglobulin antibodies after radioactive iodine therapy, the frequency of recurrent thyroid cancer was <2% in patients with >50% reduction in thyroglobulin antibodies at 1 year of follow-up. Additionally, 25% of those patients with a significant increase in thyroglobulin antibodies (>10%) were found to have recurrence at 1 year of follow-up.
WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This study has important implications in the treatment and follow-up of thyroid cancer patients. This study suggests that patients with thyroglobulin antibodies that fall >50% by 1 year after initial treatment are at low risk for thyroid cancer recurrence. On the other hand, those patients whose thyroglobulin antibodies do not change or increase have an increased risk for thyroid cancer recurrence. These results will help identify those patients that are at higher risk for thyroid cancer recurrence and, thus, should be followed more closely.
— Maria Papaleontiou, MD
ATA THYROID BROCHURE LINKS
Thyroid Cancer: http://www.thyroid.org/thyroid-cancer/
Radioactive Iodine Therapy: http://www.thyroid.org/radioactive-iodine/